A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of Ergone by UPLC-QTOF/HDMS

Ying Yong Zhao, Hua Chen, Ting Tian, Dan Qian Chen, Xu Bai, Feng Wei, Petras P Dzeja

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) is an important public health problem. Ergone has been proved to prevent the progression of CKD. UPLC-QTOF/HDMS was employed for metabolic profiling of adenine-induced CKD and to investigate the nephroprotective effects of ergone. Pharmacology parameters including blood biochemistry, histopathological evaluation and Western blot analysis were performed concurrently. The UPLC-MS data were analyzed by partial least squares-discriminate analysis, correlation analysis, heatmap analysis and mapped to KEGG pathways. Blood and serum biochemistry were observed to be significantly different in the CKD group than in the control group. In conjunction with biochemistry, histopathology and protein expression results, identified metabolites indicated perturbations in fatty acid metabolism, purine metabolism and amino acid metabolism as changes associated with adenine-induced CKD and the interventions of ergone. Upregulated expression of TGF-b1, ED-1, CTGF, bFGF and collagen I was observed in the CKD group. However, downregulated expression of these proteins was observed after oral administration of ergone. These results suggest that expression changes in these proteins had implications for fatty acid metabolism, purine metabolism and amino acid metabolism in the development of CKD and that ergone treatment could delay the development of CKD by normalizing or blocking abnormal changes in biomarker metabolites and protein expression in the CKD group.

Original languageEnglish (US)
Article numbere115467
JournalPLoS One
Volume9
Issue number12
DOIs
StatePublished - Dec 23 2014

Fingerprint

Metabolomics
metabolomics
Therapeutic Uses
kidney diseases
Chronic Renal Insufficiency
Metabolism
therapeutics
Biochemistry
fatty acid metabolism
protein synthesis
amino acid metabolism
Adenine
adenine
purines
Metabolites
biochemistry
Proteins
Blood
Fatty Acids
metabolites

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of Ergone by UPLC-QTOF/HDMS. / Zhao, Ying Yong; Chen, Hua; Tian, Ting; Chen, Dan Qian; Bai, Xu; Wei, Feng; Dzeja, Petras P.

In: PLoS One, Vol. 9, No. 12, e115467, 23.12.2014.

Research output: Contribution to journalArticle

Zhao, Ying Yong ; Chen, Hua ; Tian, Ting ; Chen, Dan Qian ; Bai, Xu ; Wei, Feng ; Dzeja, Petras P. / A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of Ergone by UPLC-QTOF/HDMS. In: PLoS One. 2014 ; Vol. 9, No. 12.
@article{fd854c7e77f643709d102df0efb12c5f,
title = "A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of Ergone by UPLC-QTOF/HDMS",
abstract = "Chronic kidney disease (CKD) is an important public health problem. Ergone has been proved to prevent the progression of CKD. UPLC-QTOF/HDMS was employed for metabolic profiling of adenine-induced CKD and to investigate the nephroprotective effects of ergone. Pharmacology parameters including blood biochemistry, histopathological evaluation and Western blot analysis were performed concurrently. The UPLC-MS data were analyzed by partial least squares-discriminate analysis, correlation analysis, heatmap analysis and mapped to KEGG pathways. Blood and serum biochemistry were observed to be significantly different in the CKD group than in the control group. In conjunction with biochemistry, histopathology and protein expression results, identified metabolites indicated perturbations in fatty acid metabolism, purine metabolism and amino acid metabolism as changes associated with adenine-induced CKD and the interventions of ergone. Upregulated expression of TGF-b1, ED-1, CTGF, bFGF and collagen I was observed in the CKD group. However, downregulated expression of these proteins was observed after oral administration of ergone. These results suggest that expression changes in these proteins had implications for fatty acid metabolism, purine metabolism and amino acid metabolism in the development of CKD and that ergone treatment could delay the development of CKD by normalizing or blocking abnormal changes in biomarker metabolites and protein expression in the CKD group.",
author = "Zhao, {Ying Yong} and Hua Chen and Ting Tian and Chen, {Dan Qian} and Xu Bai and Feng Wei and Dzeja, {Petras P}",
year = "2014",
month = "12",
day = "23",
doi = "10.1371/journal.pone.0115467",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of Ergone by UPLC-QTOF/HDMS

AU - Zhao, Ying Yong

AU - Chen, Hua

AU - Tian, Ting

AU - Chen, Dan Qian

AU - Bai, Xu

AU - Wei, Feng

AU - Dzeja, Petras P

PY - 2014/12/23

Y1 - 2014/12/23

N2 - Chronic kidney disease (CKD) is an important public health problem. Ergone has been proved to prevent the progression of CKD. UPLC-QTOF/HDMS was employed for metabolic profiling of adenine-induced CKD and to investigate the nephroprotective effects of ergone. Pharmacology parameters including blood biochemistry, histopathological evaluation and Western blot analysis were performed concurrently. The UPLC-MS data were analyzed by partial least squares-discriminate analysis, correlation analysis, heatmap analysis and mapped to KEGG pathways. Blood and serum biochemistry were observed to be significantly different in the CKD group than in the control group. In conjunction with biochemistry, histopathology and protein expression results, identified metabolites indicated perturbations in fatty acid metabolism, purine metabolism and amino acid metabolism as changes associated with adenine-induced CKD and the interventions of ergone. Upregulated expression of TGF-b1, ED-1, CTGF, bFGF and collagen I was observed in the CKD group. However, downregulated expression of these proteins was observed after oral administration of ergone. These results suggest that expression changes in these proteins had implications for fatty acid metabolism, purine metabolism and amino acid metabolism in the development of CKD and that ergone treatment could delay the development of CKD by normalizing or blocking abnormal changes in biomarker metabolites and protein expression in the CKD group.

AB - Chronic kidney disease (CKD) is an important public health problem. Ergone has been proved to prevent the progression of CKD. UPLC-QTOF/HDMS was employed for metabolic profiling of adenine-induced CKD and to investigate the nephroprotective effects of ergone. Pharmacology parameters including blood biochemistry, histopathological evaluation and Western blot analysis were performed concurrently. The UPLC-MS data were analyzed by partial least squares-discriminate analysis, correlation analysis, heatmap analysis and mapped to KEGG pathways. Blood and serum biochemistry were observed to be significantly different in the CKD group than in the control group. In conjunction with biochemistry, histopathology and protein expression results, identified metabolites indicated perturbations in fatty acid metabolism, purine metabolism and amino acid metabolism as changes associated with adenine-induced CKD and the interventions of ergone. Upregulated expression of TGF-b1, ED-1, CTGF, bFGF and collagen I was observed in the CKD group. However, downregulated expression of these proteins was observed after oral administration of ergone. These results suggest that expression changes in these proteins had implications for fatty acid metabolism, purine metabolism and amino acid metabolism in the development of CKD and that ergone treatment could delay the development of CKD by normalizing or blocking abnormal changes in biomarker metabolites and protein expression in the CKD group.

UR - http://www.scopus.com/inward/record.url?scp=84919798332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919798332&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0115467

DO - 10.1371/journal.pone.0115467

M3 - Article

C2 - 25535749

AN - SCOPUS:84919798332

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e115467

ER -